molmir and OrganoTherapeutics announce strategic R&D collaboration~ accelerate developing therapeutics for Parkinson’s disease with 3D midbrain organoids~
molmir Inc. (based in Nara, Japan, CEO: Eiichiro Mori, M.D., Ph.D.) is proud to announce that it has entered into an agreement with OrganoTherapeutics SARL (based in Esch-sur-Alzette, Luxembourg, CEO: Jens Schwamborn, Ph.D.) for R&D ...
